Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma.
The aim of this study was to assess the role of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk Hodgkin's disease (HD) compared to chemotherapy. A donor was identified in 26 patients (14 HLA identical siblings and 10 alternative donors), and 24 received a transplant (Allo group). Twenty patients without a donor received different chemotherapy regimens and radiotherapy (CHEMO group). After a median follow-up of 28 months (range: 1-110), the 2-year overall survival (OS) was 71% in the ALLO group compared to 50% in the CHEMO group (P = .031). In the Allo group, the 2-year progression-free survival (PFS) was 47%. The 1-year nonrelapse mortality (NRM) in the ALLO group was 8% versus 0% in the CHEMO group. This study, suggests that allogeneic transplantation may prolong the survival in patients with a poor-risk HD.
Castagna
Luca
L
Hematology Oncology Department, Istituto Clinico Humanitas, Rozzano, Milano, Italy. luca.castagna@humanitas.it
Sarina
Barbara
B
Todisco
Elisabetta
E
Magagnoli
Massimo
M
Balzarotti
Monica
M
Bramanti
Stefania
S
Mazza
Rita
R
Anastasia
Antonella
A
Bacigalupo
Andrea
A
Aversa
Franco
F
Soligo
Davide
D
Giordano
Laura
L
Santoro
Armando
A
D000293:Adolescent; D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006412:Hematopoietic Stem Cells; D006689:Hodgkin Disease / Q000401:mortality* / Q000628:therapy*; D006801:Humans; D019520:Living Donors; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D014184:Transplantation, Homologous